Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
As of the time of writing, retatrutide has not been granted a marketing authorisation by the MHRA or the EMA, and therefore there is no official MHRA safety guidance or Yellow Card reporting data specific to this compound in the public domain
"It's important to really stick to the guidelines for who the medication was intended for, because as providers, we always think about maximizing benefit and decreasing risk," Lofton said
doi:10.14740/jocmr3112w 61
2025 Jun 1;26(11):5338
US$ 20.55
US$ 28.53
US$ 22.18
US$ 29.20
US$ 26.13
US$ 27.19
US$ 29.67
